INBX Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -8.27%, SMA50 -9.81%, SMA200 101.1%). The stock’s 14-day RSI is 40.13 (neutral), while the ATR of 5.62 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -22.95% below its high and over 574.32% above its low. Average 10-day trading volume of 176.54 thousand shares is below the 3-month average of 388.64 thousand, indicating normal recent market interest.

The latest quarter delivered EPS of -$2.28. The next quarter is forecast at -$2.08. Next year's EPS is expected at $6.22. Inhibrx Biosciences, Inc. earnings surprise history is a mixed track record. The quarter that ended November 14, 2025, missed forecasts by 30.29%. The prior quarter beat by -22.52%. Over the last six quarters, Apple has recorded several small beats. These include -7.19% in November 14, 2024.

Inhibrx Biosciences, Inc. has 14.49 million shares outstanding. The public float is 7.81 million shares, elevated short interest at 6.45% of float. This equals 676.80 thousand shares. The short ratio is 4.92 days. Institutional investors hold 90.08% of the float. Insiders own 27.17%. Eckelman Living Trust Dated February 5, 2014 holds 2.24 million shares, Eckelman Brendan P. has 1.74 million shares and Lappe Mark has 705.55 thousand shares. Over the past six months, insider transactions show net selling. They sold 16.32 thousand shares across 1 transactions.

Inhibrx Biosciences, Inc. (NASDAQ:INBX) closed at $72.86 USD, losing -$2.34 (-3.11%) from the previous close of $75.20. The stock is currently mid-range between its 52-week high and low $10.80 and $94.56. With a market capitalization of about $1.06 billion, Inhibrx Biosciences, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.36). Key stats such as the average daily volume over the past year has been around 405.09 thousand shares, volume is running light vs its 52-week average. Headquartered in La Jolla, CA, Inhibrx Biosciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Mark Paul Lappe, the company employs approximately 156 people and listed since June 04, 2024. Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions.

Inhibrx Biosciences, Inc. last paid a dividend of 0.85 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $9.97. This means the shares are trading above this model’s fair value.

Inhibrx Biosciences, Inc. trades at a P/E ratio of -7.27, slightly below the S&P 500 average, with a price-to-sales ratio of 756.9 and a price-to-book ratio of 30.62 reflecting a rich premium to book value. The P/FCF stands at -7.39, also above market averages. Compared to sector medians, Inhibrx Biosciences, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Our AI price prediction model suggests that Inhibrx Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.62%, with price expected at $70.22 by January 23, 2026, within a range of $66.30 to $73.85 3-Month Outlook: Projected rise of 134.81%, reaching $171.08 by April 09, 2026, with a range of $170.30 to $171.80. 1-Year Outlook: Projected gain of 8.23%, with price at $78.86 by December 31, 2026, within a range of $74.26 to $85.17.

Inhibrx Biosciences, Inc. (NASDAQ:INBX) shares are flat -4.81% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Inhibrx Biosciences, Inc. trading at a premium to the broader market with a P/E of -7.27. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $40.50, suggesting -44.41% downside. Our AI forecast model points to short-term weakness (-3.62% over two weeks), a medium-term rise (134.81% over three months), and a longer-term gain (8.23% over one year), with expected trading ranges indicating moderate volatility.